Physician profile
Scott A Eader
NPI 1336178433
$4,069.57
in general payments reported to CMS, 2019-2025
20 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.21 · 2022: $642 · 2023: $1,265 · 2024: $2,009 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,358.00 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.04 | 2022-2025 | Vraylar |
| Lundbeck LLC | $464.18 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $352.10 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $287.13 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $284.55 | 2022-2024 | Spravato |
| Axsome Therapeutics, INC. | $280.43 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $278.81 | 2022-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.62 | 2022-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $223.26 | 2022-2024 | Hetlioz, Fanapt |
| Almatica Pharma LLC | $192.74 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $177.04 | 2024 | Dyanavel Xr, Quillichew Er |
| Corium, LLC | $169.33 | 2023-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $147.57 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $69.34 | 2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $58.97 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.90 | 2024 | Cobenfy |
| Neuronetics, INC. | $39.40 | 2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2023-2024 | Trintellix |
| Bausch Health US, LLC | $22.38 | 2023 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $14.92 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Eader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.